Rosiglitazone inhibits transforming growth factor-β1 mediated fibrogenesis in ADPKD cyst-lining epithelial cells

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Liu, Yawei ^a   Dai, Bing ^a   Xu, Chenggang ^a   Fu, Lili ^a   Hua, Zhenhao ^a   Mei, Changlin ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 CHLORO 5 NITROBENZANILIDE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; COLLAGEN TYPE 1; FIBRONECTIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; ROSIGLITAZONE; SCLEROPROTEIN; SMAD2 PROTEIN; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA1; 2,4 THIAZOLIDINEDIONE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SMAD2 PROTEIN, HUMAN;

ADULT; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; FEMALE; FIBROGENESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY POLYCYSTIC DISEASE; KIDNEY TUBULE EPITHELIUM; MALE; PHARMACOLOGICAL BLOCKING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; CELL CULTURE; CYST; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; EPITHELIUM CELL; FIBROSIS; KIDNEY TUBULE; METABOLISM; MIDDLE AGED; PATHOLOGY; TIME;

CELLS, CULTURED; COLLAGEN TYPE I; CYSTS; ENZYME ACTIVATION; EPITHELIAL CELLS; FEMALE; FIBRONECTINS; FIBROSIS; HUMANS; KIDNEY TUBULES; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PPAR GAMMA; RNA, SMALL INTERFERING; SMAD2 PROTEIN; THIAZOLIDINEDIONES; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 83055173874     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028915     Document Type: Article

References (50)

1. Torres VE, Harris PC, Pirson Y, (2007) Autosomal dominant polycystic kidney disease. Lancet 369: 1287-1301.
2. Harris PC, Torres VE, (2009) Polycystic kidney disease. Annu Rev Med 60: 321-337.
3. Torres VE, Harris PC, (2006) Mechanisms of Disease: autosomal dominant and recessive polycystic kidney diseases. Nat Clin Pract Nephrol 2: 40-55; quiz 55.
4. Lieske JC, Toback FG, (1993) Autosomal dominant polycystic kidney disease. J Am Soc Nephrol 3: 1442-1450.
5. Hassane S, Leonhard WN, van der Wal A, Hawinkels LJ, Lantinga-van Leeuwen IS, et al. (2010) Elevated TGFbeta-Smad signalling in experimental Pkd1 models and human patients with polycystic kidney disease. J Pathol 222: 21-31.
6. Okada H, Ban S, Nagao S, Takahashi H, Suzuki H, et al. (2000) Progressive renal fibrosis in murine polycystic kidney disease: an immunohistochemical observation. Kidney Int 58: 587-597.
7. Schieren G, Rumberger B, Klein M, Kreutz C, Wilpert J, et al. (2006) Gene profiling of polycystic kidneys. Nephrol Dial Transplant 21: 1816-1824.
8. Border WA, Noble NA, (1997) TGF-beta in kidney fibrosis: a target for gene therapy. Kidney Int 51: 1388-1396.
9. Bottinger EP, Bitzer M, (2002) TGF-beta signaling in renal disease. J Am Soc Nephrol 13: 2600-2610.
10. Miyazono K, (2000) TGF-beta signaling by Smad proteins. Cytokine Growth Factor Rev 11: 15-22.
11. Hartsough MT, Frey RS, Zipfel PA, Buard A, Cook SJ, et al. (1996) Altered transforming growth factor signaling in epithelial cells when ras activation is blocked. J Biol Chem 271: 22368-22375.
12. Leask A, Abraham DJ, (2004) TGF-beta signaling and the fibrotic response. FASEB J 18: 816-827.
13. Watanabe H, de Caestecker MP, Yamada Y, (2001) Transcriptional cross-talk between Smad, ERK1/2, and p38 mitogen-activated protein kinase pathways regulates transforming growth factor-beta-induced aggrecan gene expression in chondrogenic ATDC5 cells. J Biol Chem 276: 14466-14473.
14. Hocevar BA, Brown TL, Howe PH, (1999) TGF-beta induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway. EMBO J 18: 1345-1356.
15. Chin BY, Mohsenin A, Li SX, Choi AM, Choi ME, (2001) Stimulation of pro-alpha(1)(I) collagen by TGF-beta(1) in mesangial cells: role of the p38 MAPK pathway. Am J Physiol Renal Physiol 280: F495-504.
16. Chea SW, Lee KB, (2009) TGF-beta mediated epithelial-mesenchymal transition in autosomal dominant polycystic kidney disease. Yonsei Med J 50: 105-111.
17. Song X, Di Giovanni V, He N, Wang K, Ingram A, et al. (2009) Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational identification of gene expression pathways and integrated regulatory networks. Hum Mol Genet 18: 2328-2343.
18. Wilson PD, (1991) Aberrant epithelial cell growth in autosomal dominant polycystic kidney disease. Am J Kidney Dis 17: 634-637.
19. Schoonjans K, Martin G, Staels B, Auwerx J, (1997) Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol 8: 159-166.
20. Chawla A, Schwarz EJ, Dimaculangan DD, Lazar MA, (1994) Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 135: 798-800.
21. Spiegelman BM, (1998) PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 47: 507-514.
22. McCarthy KJ, Routh RE, Shaw W, Walsh K, Welbourne TC, et al. (2000) Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion. Kidney Int 58: 2341-2350.
23. Haraguchi K, Shimura H, Onaya T, (2003) Suppression of experimental crescentic glomerulonephritis by peroxisome proliferator-activated receptor (PPAR)gamma activators. Clin Exp Nephrol 7: 27-32.
24. Ma LJ, Marcantoni C, Linton MF, Fazio S, Fogo AB, (2001) Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int 59: 1899-1910.
25. Kawai T, Masaki T, Doi S, Arakawa T, Yokoyama Y, et al. (2009) PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta. Lab Invest 89: 47-58.
26. Dai B, Liu Y, Mei C, Fu L, Xiong X, et al. (2010) Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han:SPRD rats. Clin Sci (Lond) 119: 323-333.
27. Yoshihara D, Kurahashi H, Morita M, Kugita M, Hiki Y, et al. (2010) PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease. Am J Physiol Renal Physiol 300: F465-474.
28. Routh RE, Johnson JH, McCarthy KJ, (2002) Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro. Kidney Int 61: 1365-1376.
29. Wang W, Liu F, Chen N, (2007) Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists attenuate the profibrotic response induced by TGF-beta1 in renal interstitial fibroblasts. Mediators Inflamm pp. 62641.
30. Detrisac CJ, Sens MA, Garvin AJ, Spicer SS, Sens DA, (1984) Tissue culture of human kidney epithelial cells of proximal tubule origin. Kidney Int 25: 383-390.
31. Loghman-Adham M, Nauli SM, Soto CE, Kariuki B, Zhou J, (2003) Immortalized epithelial cells from human autosomal dominant polycystic kidney cysts. Am J Physiol Renal Physiol 285: F397-412.
32. Elberg G, Guruswamy S, Logan CJ, Chen L, Turman MA, (2008) Plasticity of epithelial cells derived from human normal and ADPKD kidneys in primary cultures. Cell Tissue Res 331: 495-508.
33. Wilson PD, Hreniuk D, Gabow PA, (1992) Abnormal extracellular matrix and excessive growth of human adult polycystic kidney disease epithelia. J Cell Physiol 150: 360-369.
34. Shibazaki S, Yu Z, Nishio S, Tian X, Thomson RB, et al. (2008) Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1. Hum Mol Genet 17: 1505-1516.
35. Li F, Zeng B, Chai Y, Cai P, Fan C, et al. (2009) The linker region of Smad2 mediates TGF-beta-dependent ERK2-induced collagen synthesis. Biochem Biophys Res Commun 386: 289-293.
36. Yue J, Frey RS, Mulder KM, (1999) Cross-talk between the Smad1 and Ras/MEK signaling pathways for TGFbeta. Oncogene 18: 2033-2037.
37. Watnick T, Germino GG, (2010) mTOR inhibitors in polycystic kidney disease. N Engl J Med 363: 879-881.
38. Zafar I, Ravichandran K, Belibi FA, Doctor RB, Edelstein CL, (2010) Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease. Kidney Int 78: 754-761.
39. Walz G, Budde K, Mannaa M, Nurnberger J, Wanner C, et al. (2010) Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 363: 830-840.
40. Serra AL, Poster D, Kistler AD, Krauer F, Raina S, et al. (2010) Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 363: 820-829.
41. Heeg MH, Koziolek MJ, Vasko R, Schaefer L, Sharma K, et al. (2005) The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway. Kidney Int 68: 96-109.
42. Li J, Zhang Z, Wang D, Wang Y, Li Y, et al. (2009) TGF-beta 1/Smads signaling stimulates renal interstitial fibrosis in experimental AAN. J Recept Signal Transduct Res 29: 280-285.
43. Hayashida T, Poncelet AC, Hubchak SC, Schnaper HW, (1999) TGF-beta1 activates MAP kinase in human mesangial cells: a possible role in collagen expression. Kidney Int 56: 1710-1720.
44. Uchiyama-Tanaka Y, Matsubara H, Nozawa Y, Murasawa S, Mori Y, et al. (2001) Angiotensin II signaling and HB-EGF shedding via metalloproteinase in glomerular mesangial cells. Kidney Int 60: 2153-2163.
45. Yamaguchi T, Pelling JC, Ramaswamy NT, Eppler JW, Wallace DP, et al. (2000) cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int 57: 1460-1471.
46. Yamaguchi T, Wallace DP, Magenheimer BS, Hempson SJ, Grantham JJ, et al. (2004) Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem 279: 40419-40430.
47. Omori S, Hida M, Fujita H, Takahashi H, Tanimura S, et al. (2006) Extracellular signal-regulated kinase inhibition slows disease progression in mice with polycystic kidney disease. J Am Soc Nephrol 17: 1604-1614.
48. Guo B, Koya D, Isono M, Sugimoto T, Kashiwagi A, et al. (2004) Peroxisome proliferator-activated receptor-gamma ligands inhibit TGF-beta 1-induced fibronectin expression in glomerular mesangial cells. Diabetes 53: 200-208.
49. Hayashida T, Decaestecker M, Schnaper HW, (2003) Cross-talk between ERK MAP kinase and Smad signaling pathways enhances TGF-beta-dependent responses in human mesangial cells. FASEB J 17: 1576-1578.
50. Li Y, Wen X, Spataro BC, Hu K, Dai C, et al. (2006) hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-gamma agonists. J Am Soc Nephrol 17: 54-65.